Not interested anymore? Unsubscribe.
Having trouble viewing this email? View it in your browser.


Pre-Announcement: AFIRM II Funding Opportunity



MRMC Homepage

Work With MRMC




No longer interested in receiving this email? Unsubscribe instantly.



I would like to update you on a funding opportunity that was just released today. For more information please review the Program Announcement below:


Defense Health Program

Joint Program Committee for Clinical and Rehabilitative Medicine Research Program



Armed Forces Institute of Regenerative Medicine – II (AFIRM II)


Program Announcement


The Armed Forces Institute of Regenerative Medicine (AFIRM) is dedicated to repairing battlefield injuries through the use of regenerative medicine technologies and associated sciences. 


The U.S. Army Medical Research and Materiel Command (USAMRMC), with the Office of Naval Research (ONR), the Air Force Medical Service, the Office of Research and Development - Department of Veterans Affairs (VA), the National Institutes of Health (NIH), and the Office of the Assistant Secretary of Defense for Health Affairs (the Sponsors) intend to solicit applications for the AFIRM II. The AFIRM II is anticipated to be funded in fiscal year 2013 (FY13).  The intent of the AFIRM II is to fund basic through translational regenerative medicine research and development.  Activities acceptable under this award may include basic scientific research, development of animal models, preclinical studies required for initiation of FDA-regulated human clinical trials, and Phase I – II human clinical trials.


The Government anticipates that Offerors will assemble an expert team from multiple academic institutions and/or industry partners to satisfy the objectives of the AFIRM II program announcement.  Offerors are expected to seek collaboration with Government laboratories and Medical Centers/Medical Treatment Facilities such as those in the Army, Navy, Air Force, NIH and VA, if mutually beneficial.


Topic Areas: The Government encourages proposals that specifically address one or more of the following focus areas:


1)       Extremity Regeneration:  With better body armor in use in contemporary warfare, the heightened prevalence of serious extremity injury on the battlefield has increased requirements to treat, reconstruct, and rehabilitate Wounded Warriors suffering massive tissue loss of the extremities. Patients typically have multiple extremity injuries, which may include damage to skin, muscle, nerve, blood vessels, bone, and connective tissues.  Consideration will be given to both hard and soft tissue regeneration, limb salvage technologies, and regenerative medicine treatment of trauma-induced damage to joints. 


a.        Soft tissue regeneration should focus on nerve, muscle and vascular injury to the extremities.


b.        Hard tissue regeneration should focus on bone injury.


c.        Limb salvage technologies should focus on adequate soft tissue coverage following multiple limb loss and/or extensive soft tissue damage, and alternatives to autologous grafts of nerve, vasculature, bone and/or soft tissues from uninjured tissue.


d.        Trauma induced damage to joints will focus on the restoration of joint structure and function, and prevention of post-traumatic arthritis.   


2)       Craniomaxillofacial Regeneration:  Craniomaxillofacial regeneration will focus on both hard and soft tissue solutions to maintain structural integrity (hold its shape) when implanted in the translational phase, integrate with the cell/environment to restore both structure and function, and maintain those attributes over time.


a.        Soft tissue regeneration should focus on nerve, muscle and vascular injury to the craniomaxillofacial region.


b.        Hard tissue regeneration should focus on well-shaped bone that maintains form and is of moderate strength (cranial and midface bones), load bearing bone that maintains 3-dimensional shape with the ability to support an articulating process (mandible), and Alveolar bone that supports dentition.


3)       Skin Regeneration:  Healing of traumatic injuries to the skin and musculoskeletal system in adults often results in the development of hypertrophic scars.  These scars lead to chronic pain, limited range of motion, poor esthetics, and require extensive therapy and rehabilitation.  Primary consideration for the skin regeneration focus area will be given to scarless wound repair and burn injury repair.


a.        Scarless wound repair efforts should focus on the control of scar formation after injury and/or treatment. Technologies that modulate the inflammatory and fibrotic response and help control scar formation and contracture are the intended focus.


b.        Full-thickness skin repair efforts should focus on next generation skin substitutes, burn injury inhibitors, and addressing complex or problematic body areas such as hands, face, and feet.



4)       Composite Tissue Allotransplantation and Immunomodulation:  Composite tissue allotransplantation efforts should focus on immunomodulation and immune tolerance technologies that promote better outcomes for composite tissue allotransplantation.  This focus area may include developing treatments or procedures for major limb amputation or facial disfiguration such as hand or face transplantation.  Additionally, this may include the development of technologies to abrogate the negative outcomes of long-term immunesuppression.


5)       Genitourinary/Lower Abdomen Reconstruction:  Genitourinary and lower abdominal reconstruction efforts should focus on pelvic and urogenital reconstruction.


a.        Pelvic reconstruction efforts should focus on promoting technologies that address injury to the anus.


b.        Urogenital reconstruction efforts should focus on promoting technologies that address injury to external genitalia (penile, scrotal, urethral tissues), perineal tissue, and bladder. 


Military Relevance: Relevance to the health care needs of the military service members, veterans, and beneficiaries is a key feature of the AFIRM II award.


The CRMRP is providing information in this pre-announcement to allow investigators time to plan and develop applications. The AFIRM II program announcement and general application instructions for the award mechanism are anticipated to be posted on in March 2012.


Application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.


All applications must conform to the final program announcement and application instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all USAMRMC funding opportunities can be obtained on the website by performing a basic search using Catalog of Federal Domestic Assistance (CFDA) Number 12.420.


A Pre-Application (Letter of Intent) is required and must be submitted through the CDMRP eReceipt website ( prior to the deadline for submission of Pre-Application (Letter of Intent).


Applications must be submitted through the federal government's single-entry portal, Submission deadlines are not available until the program announcements are released.


Point of Contact:


CDMRP Public Affairs



Thank you for your time and we look forward to hearing from you soon.




Chelsea Bauckman
Marketing Manager
United States Army Medical Research and Materiel Command